Nabuser (Nabumetone)

Nabumetone is used to manage inflammatory and degenerative joint conditions by decreasing prostaglandin‑mediated inflammation.

• Rheumatoid arthritis: alleviates joint swelling, stiffness and pain, improving functional ability and quality of life in adult patients with active disease.
• Osteoarthritis: decreases cartilage‑related discomfort and inflammation, helping patients perform daily activities with less limitation.
• Musculoskeletal pain: provides relief from acute or chronic pain associated with strains, sprains, and overuse injuries.
• Post‑operative pain: used as part of multimodal analgesia to reduce reliance on opioids.

• Nabumetone is a non‑selective cyclooxygenase (COX) inhibitor. After hepatic metabolism to its active 6‑methoxy‑2‑naphthylacetic acid metabolite, it blocks COX‑1 and COX‑2 enzymes, reducing conversion of arachidonic acid to prostaglandins. The resulting decrease in prostaglandin levels diminishes inflammation, pain and fever responses in affected tissues. By limiting prostaglandin synthesis at the site of injury, nabumetone contributes to reduced vascular permeability and leukocyte infiltration, further attenuating the inflammatory cascade.

Nabumetone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Skin rash: mild erythema or pruritus.

Serious or Rare Side Effects

• Peptic ulcer disease or gastrointestinal bleeding.
• Severe hepatic injury or hepatitis.
• Renal impairment or acute kidney injury.
• Anaphylactic reactions: swelling, bronchospasm, or hypotension.
• Blood dyscrasias: agranulocytosis or thrombocytopenia.

When prescribing nabumetone, clinicians should consider several safety precautions to minimize risk.

• Assess renal function: avoid use in patients with severe renal impairment.
• Monitor hepatic enzymes: discontinue if significant liver injury occurs.
• Evaluate gastrointestinal risk: use with caution in history of ulcers or bleeding.
• Use lowest effective dose: limit exposure to reduce cardiovascular risk.
• Avoid in hypersensitivity: discontinue if allergic reactions develop.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Nabumetone can affect the pharmacokinetics or pharmacodynamics of several medicines.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity.
• High‑dose aspirin: additive renal and gastric adverse effects.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: possible reduction in antihypertensive effect and renal function.
• Diuretics: enhanced risk of renal impairment.
• Lithium: NSAIDs may raise lithium serum levels.
• Methotrexate: reduced clearance leading to toxicity.